HAIFA, Israel, Jan. 26, 2011 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR) announced today that it intends, subject to market and other conditions, to offer its common stock and warrants to purchase its common stock in a registered public offering pursuant to its existing shelf registration statement under the Securities Act of 1933, as amended. Pluristem also intends to grant the underwriters of the offering an option to purchase additional shares of common stock and warrants to cover over-allotments, if any. Pluristem plans to use the proceeds from the offering to conduct clinical trials, research and product development activities and for general corporate purposes, including general working capital purposes. Oppenheimer & Co. Inc. is acting as the sole bookrunner and Needham & Company, LLC is acting as co-lead manager for the offering.
Pluristem Announces Proposed Public Offering Of Common Stock And Warrants To Purchase Common Stock
Check Out Our Best Services for Investors
Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Every recommendation goes through 3 layers of intense scrutinyquantitative, fundamental and technical analysisto maximize profit potential and minimize risk.
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.